These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19915448)

  • 41. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS
    AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
    Nii-Trebi NI; Ibe S; Barnor JS; Ishikawa K; Brandful JA; Ofori SB; Yamaoka S; Ampofo WK; Sugiura W
    PLoS One; 2013; 8(8):e71972. PubMed ID: 23977189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
    Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.
    Cunningham CK; Chaix ML; Rekacewicz C; Britto P; Rouzioux C; Gelber RD; Dorenbaum A; Delfraissy JF; Bazin B; Mofenson L; Sullivan JL
    J Infect Dis; 2002 Jul; 186(2):181-8. PubMed ID: 12134253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
    McIntyre JA; Hopley M; Moodley D; Eklund M; Gray GE; Hall DB; Robinson P; Mayers D; Martinson NA
    PLoS Med; 2009 Oct; 6(10):e1000172. PubMed ID: 19859531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.
    Farr SL; Nelson JA; Ng'ombe TJ; Kourtis AP; Chasela C; Johnson JA; Kashuba AD; Tegha GL; Wiener J; Eron JJ; Banda HN; Mpaso M; Lipscomb J; Matiki C; Fiscus SA; Jamieson DJ; van der Horst C;
    J Acquir Immune Defic Syndr; 2010 Aug; 54(5):515-23. PubMed ID: 20672451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Van Dyke RB; Ngo-Giang-Huong N; Shapiro DE; Frenkel L; Britto P; Roongpisuthipong A; Beck IA; Yuthavisuthi P; Prommas S; Puthanakit T; Achalapong J; Chotivanich N; Rasri W; Cressey TR; Maupin R; Mirochnick M; Jourdain G;
    Clin Infect Dis; 2012 Jan; 54(2):285-93. PubMed ID: 22144539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance.
    Lehman DA; John-Stewart GC; Overbaugh J
    PLoS Med; 2009 Oct; 6(10):e1000169. PubMed ID: 19859532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
    Bassetti D; Cargnel A
    Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    van Zyl GU; Claassen M; Engelbrecht S; Laten JD; Cotton MF; Theron GB; Preiser W
    J Med Virol; 2008 Jun; 80(6):942-6. PubMed ID: 18428139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    Ferrer E; Podzamczer D; Arnedo M; Fumero E; McKenna P; Rinehart A; Pérez JL; Barberá MJ; Pumarola T; Gatell JM; Gudiol F;
    J Infect Dis; 2003 Feb; 187(4):687-90. PubMed ID: 12599088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
    Foster C; Lyall H; Olmscheid B; Pearce G; Zhang S; Gibb DM
    HIV Med; 2009 Aug; 10(7):397-406. PubMed ID: 19459986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
    Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG
    Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
    Suksomboon N; Poolsup N; Ket-Aim S
    J Clin Pharm Ther; 2007 Jun; 32(3):293-311. PubMed ID: 17489882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
    Turriziani O; Russo G; Lichtner M; Stano A; Tsague G; Maida P; Vullo V; Antonelli G
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):781-5. PubMed ID: 18507527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
    Giuliano M; Galluzzo CM; Germinario EA; Amici R; Bassani L; Dehò L; Vyankandondera J; Mmiro F; Okong P; Vella S
    J Acquir Immune Defic Syndr; 2006 May; 42(1):131-3. PubMed ID: 16763503
    [No Abstract]   [Full Text] [Related]  

  • 58. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    Eshleman SH; Mracna M; Guay LA; Deseyve M; Cunningham S; Mirochnick M; Musoke P; Fleming T; Glenn Fowler M; Mofenson LM; Mmiro F; Jackson JB
    AIDS; 2001 Oct; 15(15):1951-7. PubMed ID: 11600822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
    Giuliano M; Guidotti G; Andreotti M; Pirillo MF; Villani P; Liotta G; Marazzi MC; Mancini MG; Cusato M; Germano P; Loureiro S; Ceffa S; Regazzi M; Vella S; Palombi L
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):286-91. PubMed ID: 17146372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.
    Machnowska P; Hauser A; Meixenberger K; Altmann B; Bannert N; Rempis E; Schnack A; Decker S; Braun V; Busingye P; Rubaihayo J; Harms G; Theuring S
    PLoS One; 2017; 12(5):e0178297. PubMed ID: 28562612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.